Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Author Correction: Phase 3 STOP-HS1 and STOP-HS2 Trials of Povorcitinib for Hidradenitis Suppurativa: Randomized, Double-Blind, Placebo-Controlled Studies

  • By

  • Martina L. Porter

  • Antonio Martorell

  • Christopher J. Sayed

  • Falk G. Bechara

  • Hadar Lev-Tov

  • Jennifer L. Hsiao

  • John W. Frew

  • Ziad Reguiaï

  • Melinda J. Gooderham

  • Noah Goldfarb

  • Hessel H. van der Zee

  • Veronique del Marmol

  • Angelo V. Marzano

  • Benjamin D. Ehst

  • Lindsay S. Ackerman

  • Koremasa Hayama

  • Chenwei Tian

  • Jennifer Kelley

  • Huiling Zhen

  • Joslyn S. Kirby

  • Kurt Brown

  • Leandro L. Santos

  • Christos C. Zouboulis

  • October 21, 2026

Share

  • 1

    The correction updates the reported baseline HS disease-duration range to 9.7 (0.4−49.1)−10.8 (0.4−57.7) years.

  • 2

    The revised Fig. 1 legend states that three STOP-HS2 patients stopped treatment after week 12: two by physician decision and one by withdrawal.

  • 3

    Fig. 1 footnote d now states that one patient withdrew after completing treatment through week 12.

  • 4

    In Table 2, STOP-HS1 75-mg P values for the Skin Pain NRS outcomes carry superscript f instead of e.

  • 5

    The correction also revises Extended Data Fig. 5e,f and reorders the Week 12 values in Supplementary Table 6A; the HTML and PDF versions were corrected.

Original Source(s)

Author Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials

  • by Martina L. Porter, Antonio Martorell, Christopher J. Sayed, Falk G. Bechara, Hadar Lev-Tov, Jennifer L. Hsiao, John W. Frew, Ziad Reguiaï, Melinda J. Gooderham, Noah Goldfarb, Hessel H. van der Zee, Veronique del Marmol, Angelo V. Marzano, Benjamin D. Ehst, Lindsay S. Ackerman, Koremasa Hayama, Chenwei Tian, Jennifer Kelley, Huiling Zhen, Joslyn S. Kirby, Kurt Brown, Leandro L. Santos, Christos C. Zouboulis

  • October 21, 2026

Related Content

Vitamin D may ease cancer treatment skin toxicity

Most patients reported symptom relief within 10 days, while 73% continued anticancer therapy without interruption.

Beyond Drainage: Clinical–Ultrasound Correlation Supports a Broader Definition of the Active Tunnel in Hidradenitis Suppurativa

Symposium on Hidradenitis Suppurativa Advances 2025 Proceedings